Welcome to our dedicated page for AGIOS PHARMACEUTICALS SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agios Pharmaceuticals, Inc. filings document the regulatory record of a Delaware, Nasdaq-listed commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its 8-K reports furnish operating results, product revenue updates for PYRUKYND® and AQVESME™, business highlights, investor presentations, and Regulation FD disclosures tied to mitapivat commercialization, clinical programs, and regulatory interactions.
Proxy and current-report filings cover annual-meeting proposals, director elections, board-class structure, committee assignments, stockholder voting matters, and compensatory arrangements for directors. Other disclosures address board appointments, pharmacovigilance communications involving PYRUKYND, exhibit filings, and Inline XBRL cover-page data.
Agios Pharmaceuticals, Inc. (AGIO) filed a Form S-8 on 18 June 2025 to register additional shares under its 2023 Stock Incentive Plan, as amended. The filing is purely administrative and incorporates by reference the prior S-8 (File No. 333-272615, filed 13 June 2023), with the only new content being updated exhibits and signatures.
The registration enables the continued issuance of equity-based compensation to employees, directors and consultants. Exhibits include the company’s Restated Certificate of Incorporation, current By-laws, the updated plan document, the legal opinion of Wilmer Cutler Pickering Hale and Dorr LLP, the PwC consent, and filing-fee calculations. No financial statements, earnings data or transactional details are provided.
Because Form S-8 does not itself issue shares but merely registers them for potential future grants, there is no immediate cash impact. However, any subsequent grants will add to the company’s share count and could modestly dilute existing shareholders.